L-palmitoylcarnitine | 2364-66-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: L-palmitoylcarnitine
• 英文别名: (+)-Palmitoylcarnitine；(3S)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate
• CAS: 2364-66-1
• 化学式: C₂₃H₄₅NO₄
• 分子量: 399.615
• InChiKey: XOMRRQXKHMYMOC-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  28
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Method for normalization in metabolomics analysis methods with endogenous reference metabolites
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2270699A1

  公开（公告）日：2011-01-05

  The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.

  本发明涉及内源参比代谢物的使用以及对哺乳动物受试者生物样本中选定目标代谢物的量和/或浓度对应的强度数据进行归一化的方法，其中所述强度数据是通过一种或多种内源参比代谢物的代谢组学分析方法获得的、包括对所述生物样本中的所述选定目标代谢物进行至少一种体外代谢组学分析方法，同时对同一样本中的一种或多种内源性参考代谢物或其衍生物进行定量分析，其中所述内源性参考代谢物是生物样本中的化合物，它们以基本恒定的水平存在于受试者体内；所述内源性参考代谢物或其衍生物的分子质量小于 1500 Da。
• Methods of expressing products in mammalian cells
  申请人：Intrexon CEU, INC.

  公开号：US10000770B2

  公开（公告）日：2018-06-19

  The invention relates to newly identified selectable marker systems, cells for use in a selectable marker system, and methods for using the selectable marker systems.

  本发明涉及新发现的可选择标记系统、用于可选择标记系统的细胞以及使用可选择标记系统的方法。
• Graphite electrode comprising electrochemically reduced graphene oxide and methods thereof
  申请人：KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS

  公开号：US10156539B2

  公开（公告）日：2018-12-18

  A modified graphite electrode comprising a coating of electrochemically reduced graphene oxide. The modified graphite electrode may be employed in detecting of uric acid. A sensing device comprising the modified graphite electrode and a method of making the modified graphite electrode are described herein.

  一种改性石墨电极，包括一层电化学还原氧化石墨烯涂层。改性石墨电极可用于检测尿酸。本文描述了一种包含改性石墨电极的传感装置和一种制造改性石墨电极的方法。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。
• Water soluble compositions and methods of making the same
  申请人：Nulixir Inc.

  公开号：US11351117B2

  公开（公告）日：2022-06-07

  Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

  提供了一种用于口服的组合物，该组合物包括：分散介质，其中包括：水溶液；以及分散相，其中包括：颗粒群，每个颗粒包括：核心，其中包括：第一活性成分；以及水溶液；外壳，基本上围绕在核心周围，外壳包括：亲脂性载体；以及多种乳化剂；其中，颗粒在服用后可延缓第一活性成分的释放。